Clinical Trials Browser

Unknown × Interventional × regorafenib × Clear all

NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Phase 2 Unknown

12 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06283303 2024-02-29

A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05962450 2024-01-16

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT06200363 2024-01-11

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

Advanced Colorectal Cancer

NCT05370807 2023-10-24

RegoMel

Phase 2 Unknown

Melanoma

NCT06089330 2023-10-18

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05818267 2023-07-14

Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)

Phase NA Unknown

Gastrointestinal

Colorectal Neoplasms

NCT02365441 2023-07-07

ALT GIST

Phase 2 Unknown

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05382741 2023-05-17

VIVA

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05134532 2023-04-26

HCC

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05048017 2023-03-29

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT02619435 2023-03-24

STREAM

Phase 2 Unknown

Gastrointestinal

Advanced Colorectal Cancer

NCT04030260 2023-03-23

Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Cancer Metastatic

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT05644392 2022-12-09

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Phase 1 Unknown

Gastrointestinal

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

NCT04718909 2022-11-10

REGSIN

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05535647 2022-09-10

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT05524155 2022-09-01

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05485909 2022-08-03

Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

Phase 2 Unknown

Gastrointestinal

Colorectal Cancer Liver Metastases

NCT05426811 2022-06-29

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Phase NA Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT02773524 2022-01-13

INTEGRATEIIa

Phase 3 Unknown

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT05130021 2021-12-06

A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT02501551 2021-04-05

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Phase 2 Unknown

Melanoma

NCT04819516 2021-03-29

Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04110093 2020-12-30

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT02162914 2020-07-31

REACHIN

Phase 2 Unknown

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT03946917 2020-05-12

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04008511 2019-07-05

Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT03880877 2019-03-21

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT01949194 2018-08-10

Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT02288078 2014-11-13

Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)

Phase 2 Unknown

Gastrointestinal

Fatigue, Rectal Neoplasms

NCT01189903 2014-01-28

Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients

Phase 2/3 Unknown

Gastrointestinal

Asian Colorectal Cancer Patients